Study on up-regulation of the expression of angiotensin-converting enzyme-2 in human umbilical vein endothelial cells by telmisartan

OBJECTIVE: To investigate the effect of telmisartan on the protein and gene expression of angiotensin-converting enzyme-2 (ACE2) in human umbilical vein endothelial cells (HUVECs)

Bibliographische Detailangaben
Veröffentlicht in:Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue. - 1998. - 18(2006), 4 vom: 29. Apr., Seite 224-8
1. Verfasser: Wang, Li-jun (VerfasserIn)
Weitere Verfasser: Ma, Hong, Liao, Xin-xue, Hu, Xue-song, Tian, Fang, Gu, Hai-bo, Hao, Yan-hua, Cai, Yi-ming, Peng, Long-yun, He, Jian-gui, Zeng, Wu-tao, Leng, Xiu-yu
Format: Aufsatz
Sprache:Chinese
Veröffentlicht: 2006
Zugriff auf das übergeordnete Werk:Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Benzimidazoles Benzoates RNA, Messenger Peptidyl-Dipeptidase A EC 3.4.15.1 ACE2 protein, human EC 3.4.17.23 Angiotensin-Converting Enzyme 2 mehr... Telmisartan U5SYW473RQ
LEADER 01000caa a22002652 4500
001 NLM162308868
003 DE-627
005 20250207070730.0
007 tu
008 231223s2006 xx ||||| 00| ||chi c
028 5 2 |a pubmed25n0541.xml 
035 |a (DE-627)NLM162308868 
035 |a (NLM)16647014 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Wang, Li-jun  |e verfasserin  |4 aut 
245 1 0 |a Study on up-regulation of the expression of angiotensin-converting enzyme-2 in human umbilical vein endothelial cells by telmisartan 
264 1 |c 2006 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 05.01.2010 
500 |a Date Revised 09.12.2020 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a OBJECTIVE: To investigate the effect of telmisartan on the protein and gene expression of angiotensin-converting enzyme-2 (ACE2) in human umbilical vein endothelial cells (HUVECs) 
520 |a METHODS: HUVECs were treated with various concentrations of telmisartan (10(-7), 10(-6) and 10(-5) mol/L) for 24 hours. In a time-control experiment, HUVECs were treated with telmisartan at the final concentration of 10(-6) mol/L for 6, 12 and 24 hours, respectively. In another experiment, HUVECs were treated with PD123319 (10(-6) mol/L) only or combined with same final concentration of telmisartan for 12 hours, respectively. Changes in both protein and gene expression of ACE2 were determined with Western blot analysis and reverse transcription-polymerase chain reaction (RT-PCR) technique, respectively 
520 |a RESULTS: Telmisartan induced a concentration and time dependent increase in both protein and gene expression of ACE2 (P<0.05 or P<0.01). Compared with control group, treatment of HUVECs with telmisartan at the concentration of 10(-7), 10(-6) and 10(-5) mol/L stimulated 1.5-, 2.7- and 4.6-fold increase in the ACE2 protein expression, as well as 1.2-, 2.3- and 4.5-fold increase in its gene expression, respectively. After treatment of HUVECs with telmisartan for 6, 12, and 24 hours at the concentration of 10(-6) mol/L, the ACE2 protein expression increased 1.6-, 2.7- and 4.2-fold, and its gene expression increased 1.3-, 2.3- and 4.0-fold, respectively. Compared with control and telmisartan groups, PD123319 had no effect on both protein and gene expression of ACE2 (P>0.05) 
520 |a CONCLUSION: Telmisartan up-regulates the protein and gene expression of ACE2 in HUVECs in a concentration and time dependent manner. This effect may be mediated via its specific pathway 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Benzimidazoles  |2 NLM 
650 7 |a Benzoates  |2 NLM 
650 7 |a RNA, Messenger  |2 NLM 
650 7 |a Peptidyl-Dipeptidase A  |2 NLM 
650 7 |a EC 3.4.15.1  |2 NLM 
650 7 |a ACE2 protein, human  |2 NLM 
650 7 |a EC 3.4.17.23  |2 NLM 
650 7 |a Angiotensin-Converting Enzyme 2  |2 NLM 
650 7 |a EC 3.4.17.23  |2 NLM 
650 7 |a Telmisartan  |2 NLM 
650 7 |a U5SYW473RQ  |2 NLM 
700 1 |a Ma, Hong  |e verfasserin  |4 aut 
700 1 |a Liao, Xin-xue  |e verfasserin  |4 aut 
700 1 |a Hu, Xue-song  |e verfasserin  |4 aut 
700 1 |a Tian, Fang  |e verfasserin  |4 aut 
700 1 |a Gu, Hai-bo  |e verfasserin  |4 aut 
700 1 |a Hao, Yan-hua  |e verfasserin  |4 aut 
700 1 |a Cai, Yi-ming  |e verfasserin  |4 aut 
700 1 |a Peng, Long-yun  |e verfasserin  |4 aut 
700 1 |a He, Jian-gui  |e verfasserin  |4 aut 
700 1 |a Zeng, Wu-tao  |e verfasserin  |4 aut 
700 1 |a Leng, Xiu-yu  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue  |d 1998  |g 18(2006), 4 vom: 29. Apr., Seite 224-8  |w (DE-627)NLM098227793  |x 1003-0603  |7 nnns 
773 1 8 |g volume:18  |g year:2006  |g number:4  |g day:29  |g month:04  |g pages:224-8 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 18  |j 2006  |e 4  |b 29  |c 04  |h 224-8